OTC · Biotechnology

Avecho Biotechnology Limited (AVEFF) Stock

$0.00 OTC: AVEFF Healthcare

Avecho Biotechnology Limited is an Australian-based firm specializing in the development, production, and sale of various products. Central to its operations is the proprietary and patented Targeted Penetration Matrix (TPM) drug delivery system, which the company leverages across the pharmaceutical, skincare, animal health, and nutrition industries.

Valuation

MetricValue
Price$0.00
Market Cap$13.35M
P/E Ratio-15.71
P/B Ratio6.68
P/S Ratio13.35
EPS (TTM)$0.00
52-Week High$0.00
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-200.00%
ROA-57.14%
ROCE-93.86%
Gross Margin-600.00%
Operating Margin-600.00%
Net Margin-400.00%
Debt/Equity0.00
Current Ratio7.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$1.0M$0$1.0M$1.0M
Operating Profit$-5.0M$-3.0M$-5.0M$-5.0M$-6.0M
Net Profit$-3.0M$-2.0M$-3.0M$-3.0M$-4.0M
EPS$0.00$0.00$0.00$0.00$0.00
Op Margin-573.5%-254.1%-969.1%-370.7%-485.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$5.0M$3.0M$7.0M$5.0M$7.0M
Total Liabilities$1.0M$1.0M$1.0M$2.0M$6.0M
Cash$3.0M$1.0M$6.0M$2.0M$5.0M
Borrowings$0$0$0$1.0M$0

Latest News

Positive interim analysis advances Avecho Phase III insomnia program PR Newswire · Jun 29, 2026 Avecho completes treatment phase for Phase III insomnia trial interim analysis Proactive · May 21, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-3.0M$-2.0M$-3.0M$-4.0M$1.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$1.0M$-2.0M$4.0M$-3.0M$2.0M
Free Cash Flow$-3.0M$-2.0M$-3.0M$-4.0M$1.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.16
EV / EBITDA-10.33
FCF Yield-1.78%
Quick Ratio9.94
Interest Coverage-13.01
Return 1Y0.00%
Return 3Y28.57%
Return 5Y—

Ownership

Insiders Held27.02%
Institutions Held0.00%
Institutions Float Held0.00%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Avecho Biotechnology Limited

Avecho Biotechnology Limited is an Australian-based firm specializing in the development, production, and sale of various products. Central to its operations is the proprietary and patented Targeted Penetration Matrix (TPM) drug delivery system, which the company leverages across the pharmaceutical, skincare, animal health, and nutrition industries. Its product portfolio includes TPM and Vital ET, which are incorporated into drug delivery systems and cosmetic formulations. The company is also actively engaged in the development of TPM/Oxymorphone and TPM/Oxycodone. For human health, Avecho's offerings facilitate drug administration through diverse methods such as gels, injectables, and transdermal patches. Additionally, it provides non-antibiotic feed additives aimed at enhancing the health and feed efficiency of livestock. Avecho demonstrates its commitment to research through a collaboration with the Lambert Initiative at the University of Sydney, jointly conducting a study to explore the potential of topically applied cannabidiol for alleviating osteoarthritis symptoms. The company's reach extends internationally, serving clients in Australia, Switzerland, India, and other global markets. Founded in 1992, the company was previously known as Phosphagenics Limited before adopting the name Avecho Biotechnology Limited in May 2019. Its headquarters are situated in Clayton, Australia.

Avecho Biotechnology Limited (AVEFF) stock trades at $0.00 with a market capitalization of $13.35M. The stock is valued at a price-to-earnings (P/E) ratio of -15.71, price-to-book of 6.68, price-to-sales of 13.35. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Avecho Biotechnology Limited generates a return on equity (ROE) of -200.00%, return on capital employed of -93.86%, an operating margin of -600.00%, a net profit margin of -400.00%.

Official website: avecho.com.au

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides